Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Correlia Biosystems
AddedFeb 15, 2024
UpdatedJul 3, 2026
Correlia Biosystems

Correlia Biosystems

Closed

Correlia Biosystems: Innovating microscale tools for rapid biomolecule quantification.

HQ
Berkeley, CA, US
Founded
2013
Accelerator
Y Combinator logoY CombinatorW18
Overview
Compare
Fundraising
Employees

Correlia Biosystems, a UC Berkeley spinoff based in Berkeley, CA, is dedicated to revolutionizing biomolecule quantification through innovative microscale tools. Their core mission is to provide next-gen blood testing that delivers 1000x more data to pharmaceutical companies. The company's flagship product, "SimpleScan," enables rapid and dynamic monitoring of protein expression profiles from just one microliter of sample. This technology has applications in next-gen proteomics and point-of-care diagnostics, aiming to open new biological research avenues.

Notable figures affiliated with Correlia Biosystems include experts from UC Berkeley, contributing to its strong academic foundation. The company has attracted significant interest from investors focused on cutting-edge biotech innovations. Key achievements include the successful development and implementation of the SimpleScan technology, which has garnered attention for its efficiency and potential impact on pharmaceutical research and diagnostics. Overall, Correlia Biosystems is poised to make substantial contributions to data-driven biology and personalized medicine.

Correlia Biosystems - Similar Companies

Probius logo

Probius

probius.bio

Signatur Biosciences logo

Signatur Biosciences

signatur.bio

Spear Bio logo

Spear Bio

spear.bio

Fluidigm logo

Fluidigm

standardbio.com

Scribe Biosciences logo

Scribe Biosciences

Aperture Bio logo

Aperture Bio

aperture.bio

PreDxion Bio logo

PreDxion Bio

predxionbio.com

Syncell logo

Syncell

syncell.com

Enable Biosciences logo

Enable Biosciences

Envivo Bio logo

Envivo Bio

envivo.bio

BioChip Labs logo

BioChip Labs

biochiplabs.com

Newomics logo

Newomics

newomics.com

Solus Biosystems logo

Solus Biosystems

BioFluidica logo

BioFluidica

biofluidica.com

BioAnalytics logo

BioAnalytics

Correlia Biosystems - Quick Facts

Who are Correlia Biosystems' competitors?

Companies similar to Correlia Biosystems include Probius, Signatur Biosciences, Spear Bio and Fluidigm.

When was Correlia Biosystems founded?

Correlia Biosystems was founded in 2013.

Where is Correlia Biosystems' headquarters located?

Correlia Biosystems' headquarters is located in Berkeley, CA, US.

When was Correlia Biosystems' last funding round?

Correlia Biosystems' most recent funding round was for $9.6M (USD) in October 2020.

How much has Correlia Biosystems raised to-date?

As of Oct 16, 2020, Correlia Biosystems has raised a total of $10.7M (USD).

Correlia Biosystems - Classification

Ownership
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Blood Testing
Tags
  • API
  • Biotech
  • Data
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software